Skip to content

Investors / Publications


The following publications, posters and citations are provided for investors and should not be construed as marketing the use of any Amarin products or product candidates. Copyright to certain documents referenced below are held by their publishers. Where possible, a link is provided for access to further information about the respective publication. Note that AMR101 is the clinical name for Vascepa® (icosapent ethyl) capsules. For more information about Vascepa® (icosapent ethyl) capsules visit www.vascepa.com.

To print all contents as a single document click the print icon on the upper right.

In Chronological Order

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT Jr, Juliano RA. Usefulness of icosapent ethyl (eicosapentaenoic acid ethyl ester) in women to lower triglyceride levels (results from the MARINE and ANCHOR trials). Am J Cardiol. 2017; 119:397-403.
Free:
http://www.ajconline.org/article/S0002-9149(16)31738-6/pdf

Bays HE, Ballantyne CM, Doyle Jr RT, Juliano RA, Philip S. Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016;125:57-64.
Free:
http://www.sciencedirect.com/science/article/pii/S1098882316300545

Ballantyne CM, Bays HE, Philip S, Doyle Jr RT, Braeckman RA, Stirtan WG, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016;253:81-87.
Free:
http://www.atherosclerosis-journal.com/article/S0021-9150(16)31254-0/fulltext

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle Jr RT, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10:635-645.
Free:
http://www.lipidjournal.com/article/S1933-2874(15)30076-3/pdf

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome.. Metab Syndr Relat Disord. 2015;13:239-247.
Free:
http://online.liebertpub.com/doi/pdfplus/10.1089/met.2014.0137

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR study). J Clin Lipidol. 2015;9:377-383.
Free:
http://www.lipidjournal.com/article/S1933-2874(14)00408-5/pdf

Braeckman RA, Stirtan WG, Soni PN. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Clin Drug Investig. 2015;35:45-51.
http://link.springer.com/article/10.1007/s40261-014-0252-8

Braeckman RA, Stirtan WG, Soni PN. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects. Clin Pharmacol Drug Dev. 2015;4:143-148.
Free:
http://onlinelibrary.wiley.com/doi/10.1002/cpdd.150/pdf

Braeckman RA, Stirtan WG, Soni PN. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults. Drugs R D. 2014;14:159-164.
Free:
http://link.springer.com/article/10.1007%2Fs40268-014-0053-9

Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters. Clin Drug Investig. 2014;34:449-456.
http://link.springer.com/article/10.1007/s40261-014-0194-1

Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Devel. 2013;3:101-108.
Free:
http://onlinelibrary.wiley.com/doi/10.1002/cpdd.84/pdf

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukotrienes Essent Fatty Acids. 2013;89:195-201.
http://dx.doi.org/10.1016/j.plefa.2013.07.005

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100.
Free:
http://www.cardiab.com/content/pdf/1475-2840-12-100.pdf

Ballantyne CM, Braeckman RA, Soni PN. Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin. Pharmacother. 2013;14:1409-1416.
http://informahealthcare.com/doi/abs/10.1517/14656566.2013.798645

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13:37-46.
Free:
http://link.springer.com/article/10.1007/s40256-012-0002-3

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984-992.
Free:
http://triglyceridespanel.ajconline.org/Content/PDFs/1-Ballantyne-Efficacy.pdf

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6:565-572.
Free:
http://triglyceridespanel.ajconline.org/Content/PDFs/2-Bays-Icosapent.pdf

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682-690.
Free:
http://triglyceridespanel.ajconline.org/Content/PDFs/3-Bays-Eicosapentaenoic.pdf

Recent Amarin Scientific Presentations

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Chowdhury S, Doyle RT, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in statin-treated women with persistent high triglycerides: results from the ANCHOR study [abstract 15922]. Circulation. 2016;134(suppl 1):A15922.

Brinton EA, Ballantyne CM, Bays HE, Cromwell W, Otvos J, Philip S, Doyle RT, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides: ANCHOR patients with diabetes mellitus [abstract 1173-P]. Diabetes. 2016;65(suppl 1):A308.

Mosca L, Bays H, Philip S, Chowdhury S, Doyle Jr R, Juliano R. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in women with very high triglyceride levels: results from the MARINE study [abstract 164]. J Clin Lipidol. 2016;10:701-702.
http://www.lipidjournal.com/article/S1933-2874(16)30113-1/fulltext

Full Bibliography of Amarin Scientific Presentations AT SOCIETY MEETINGS

American College of Cardiology

Bays HE, Philip S, Chowdhury S, Doyle R, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in statin-treated patients with elevated cardiovascular risk and very high triglyceride levels: results from the MARINE study [abstract]. J Am Coll Cardiol. 2016;67(suppl):1950.
Free:
http://content.onlinejacc.org/article.aspx?articleid=2510327#tab1

American Diabetes Association

Brinton EA, Ballantyne CM, Bays HE, Cromwell W, Otvos J, Philip S, Doyle RT, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides: ANCHOR patients with diabetes mellitus [abstract 1173-P]. Diabetes. 2016;65(suppl 1):A308.

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract 629-P]. Diabetes. 2012;61(suppl 1):A159-A160.

American Heart Association

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Chowdhury S, Doyle RT, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in statin-treated women with persistent high triglycerides: results from the ANCHOR study [abstract 15922]. Circulation. 2016;134(suppl 1):A15922.

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract]. Circulation. 2014;130:A16803.

Bays H, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. High-sensitivity C-reactive protein effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) with and without stable statin therapy in hypertriglyceridemic patients with metabolic syndrome [abstract]. Circulation. 2013;128:A19342.

Braeckman R, Bays HE, Ballantyne CM, Stirtan WG, Soni PN. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract]. Circulation. 2013;128:A19343.

Braeckman RA, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101 lowers triglycerides, atherogenic lipoprotein, phospholipase A2, and high-sensitivity C- reactive protein levels in patients with high triglycerides and on background statin therapy (the ANCHOR study) [abstract]. Circulation. 2011;124:A15071.

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Effects of AMR101, a pure ethyl eicosapentaenoic acid omega-3 fatty acid, on lipoprotein particle concentration and size in patients with very high triglycerides (the MARINE study) [abstract]. Circulation. 2011;124:A14232.

European Society of Cardiology

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT, Soni PN, Juliano R. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract P1679]. Eur Heart J. 2015;36(suppl 1):287.

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract]. Eur Heart J. 2012;33(suppl 1):280.

Bays HE, Ballantyne CM, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study [abstract]. Eur Heart J. 2011;32(suppl 1):342.

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE trial) [abstract]. Eur Heart J. 2011;32(suppl 1):510-511.

International Society for the Study of Fatty Acids and Lipids

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE study) [abstract]. Presented at: Congress of the International Society for the Study of Fatty Acids and Lipids, Vancouver, Canada, May 26-30, 2012.

Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with AMR101 (ethyl-eicosapentaenoic acid) in healthy subjects [abstract]. Presented at: Congress of the International Society for the Study of Fatty Acids and Lipids, Vancouver, Canada, May 26-30, 2012.

Kern Lipid Conference

Juliano RA, Braeckman RA, Manku MS, Ballantyne CM, Doyle RT Jr, Soni PN, Stirtan WG. Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Presented at: The Kern Lipid Conference, August 3-5, 2015, Vail, Colorado.

National Lipid Association

Mosca L, Bays H, Philip S, Chowdhury S, Doyle Jr R, Juliano R. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in women with very high triglyceride levels: results from the MARINE study [abstract 164]. J Clin Lipidol. 2016;10:701-702.
http://www.lipidjournal.com/article/S1933-2874(16)30113-1/fulltext

Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract 172]. J Clin Lipidol. 2015;9:463-4.

Stirtan WG, Braeckman RA, Bays HE, Ballantyne CM, Soni PN, Juliano RA. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract 173]. J Clin Lipidol. 2015;9:464.

Ballantyne CM, Bays HE, Braeckman RA, Stirtan WG, Doyle RT Jr, Juliano R, Soni PN. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract]. J Clin Lipidol. 2014;8:313-314.

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos J, Stirtan WG, Soni PN. Effects of icosapent ethyl on lipoprotein particle concentration and the fatty acid desaturation index in statin-treated patients with persistent high triglycerides (the ANCHOR study) [abstract]. J Clin Lipidol. 2013;7:270-271.

Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on atorvastatin pharmacokinetics in healthy subjects [abstract]. J Clin Lipidol. 2013;7:269-270.

Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetics and anticoagulation pharmacodynamics in healthy subjects [abstract]. J Clin Lipidol. 2013;7:270.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. AMR101, a pure ethyl eicosapentaenoic acid omega-3 fatty acid: effects on inflammation-associated end points from the MARINE and ANCHOR study [abstract]. J Clin Lipidol. 2012;6:279.

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. The effect of two doses of AMR101 on fasting serum triglycerides and other lipid parameters in statin-treated patients with persistent high triglycerides (200 and <500 mg/dL): the ANCHOR study [abstract]. J Clin Lipidol. 2012;6:279-280.

Bays HE, Ballantyne CM, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study [abstract]. J Clin Lipidol. 2011;5:205.

Obesity Society

Braeckman R, Stirtan W, Soni PN. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects [abstract T- 755-P]. Presented at the Annual Obesity Week meeting, November 11-16, 2013, Atlanta, Georgia. Available online at: Page S226 http://www.obesity.org/images/TOS_Abstract_Book_FINAL_Posters_for_web2.pdf

Bays H, Ballantyne CM, Braeckman R, Stirtan W, Soni PN. Icosapent ethyl (eicosapentaenoic acid ethyl ester) therapy in hypertriglyceridemic stable-statin-treated patients with metabolic syndrome: effect on high-sensitivity C-reactive protein levels [abstract T-737- P]. Presented at the Annual Obesity Week meeting, November 11-16, 2013, Atlanta, Georgia. Available online at: Page S222 http://www.obesity.org/images/TOS_Abstract_Book_FINAL_Posters_for_web2.pdf

In Chronological Order

Brinton EA, Mason RP. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids in Health and Disease. 2017; epub ahead of print.
Free:
https://lipidworld.biomedcentral.com/articles/10.1186/s12944-017-0415-8

 

Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Comm. 2017;483:425-429.
Free:
http://www.sciencedirect.com/science/article/pii/S0006291X16321878

 

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT Jr, Juliano RA. Usefulness of icosapent ethyl (eicosapentaenoic acid ethyl ester) in women to lower triglyceride levels (results from the MARINE and ANCHOR trials). Am J Cardiol. 2017;119:397-403.
Free:
http://www.ajconline.org/article/S0002-9149(16)31738-6/pdf

 

Handelsman Y, Shapiro MD. Triglycerides, atherosclerosis, and cardiovascular outcome studies: focus on omega-3 fatty acids. Endocr Pract. 2017 Jan;23(1):100-112.
Free:
http://journals.aace.com/doi/pdf/10.4158/EP161445.RA

 

Mason RP, Jacob RF, Shrivastava S, Sherratt SC, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858(12):3131-3140.
Free:
http://www.sciencedirect.com/science/article/pii/S0005273616303297

 

Crandell JR, Tartaglia C, Tartaglia J. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. Postgrad Med. 2016; epub ahead of print.
http://www.tandfonline.com/doi/abs/10.1080/00325481.2016.1241129

 

Crandell JR. Switching from EPA + DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl) in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk: a case study. Clin Med Insights Cardiol. 2016;10:123-128.
http://www.la-press.com/switching-from-epa--dha-omega-3-acid-ethyl-esters-to-high-purity-epa-i-article-a5790

 

Philip S, Chowdhury S, Nelson JR, Benjamin Everett P, Hulme-Lowe CK, Schmier JK. A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. J Med Econ. 2016; epub ahead of print.
http://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1207652

 

Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.
http://www.ajconline.org/article/S0002-9149(16)30484-2/pdf

 

Reddy KJ, Chowdhury S. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements. Future Cardiol. 2016;12:261-268.
Free:
http://www.futuremedicine.com/doi/pdf/10.2217/fca-2015-0009

 

Fialkow J. Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products. Am J Cardiovasc Drugs. 2016;16:229-239.
Free:
http://link.springer.com/article/10.1007/s40256-016-0170-7

 

Tajuddin N, Shaikh A, Hassan A. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:109-118.
Free:
https://www.dovepress.com/prescription-omega-3-fatty-acid-products-considerations-for-patients-w-peer-reviewed-article-DMSO (to obtain PDF, click “download” button; PDF is downloaded to C drive download folder)

 

Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68:33-40.
Free:
http://journals.lww.com/cardiovascularpharm/Fulltext/2016/07000/Eicosapentaenoic_Acid_Inhibits_Oxidation_of.5.aspx

 

Castaldo RS. Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series. Drugs Ther Perspect. 2016;32:162-9.
Free:
http://link.springer.com/article/10.1007/s40267-016-0288-3

 

Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. Curr Med Res Opin. 2016;32:301-11.
http://www.tandfonline.com/doi/abs/10.1185/03007995.2015.1120190?journalCode=icmo20

 

Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;January:46-52B.
http://www.managedcaremag.com/sites/default/files/imported/1601/ManagedCare_201601.pdf

 

Ito MK. A comparative overview of prescription omega-3 fatty acid products. P&T. 2015;40:826-857.
Free:
http://www.formkit.com/journal/article/full/2015/12/826/comparative-overview-prescription-omega-3-fatty-acid-products

 

Kedia AW, Lynch E. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Postgrad Med. 2015;127:869-873.
http://www.tandfonline.com/doi/full/10.1080/00325481.2015.1100086

 

Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. Curr Med Res Opin. 2016;32:301-311.
http://www.tandfonline.com/doi/abs/10.1185/03007995.2015.1120190?journalCode=icmo20

 

Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357-366.
Free:
http://www.atherosclerosis-journal.com/article/S0021-9150(15)30055-1/pdf

 

Mason RP, Jacob RF. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim Biophys Acta. 2015;1848:502-509.
Free:
http://dx.doi.org/10.1016/j.bbamem.2014.10.016

 

Hassan A, Tajuddin N, Shaikh A. Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl. Cardiol Ther. 2015;4:83-93.
Free:
http://link.springer.com/article/10.1007/s40119-014-0032-9

 

Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126:7-18.
Free:
https://postgradmed.org/doi/10.3810/pgm.2014.11.2828

 

Castaldo RS. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients. Postgrad Med. 2014;126:268-273.
https://postgradmed.org/doi/10.3810/pgm.2014.05.2775

 

Jacobson TA. Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. Clin Lipidol. 2014;9:149-161.
http://www.futuremedicine.com/doi/abs/10.2217/clp.14.10

 

Hilleman DE, Malesker MA. Potential benefits of icosapent ethyl on the lipid profile: case studies. Clin Med Insights Cardiol. 2014;8:13-15.
Free:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914996/pdf/cmc-8-2014-013.pdf

 

Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. P&T. 2013;38:681-691.
Free:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875260/pdf/ptj3811681.pdf

 

Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis. 2013;230:381-389.
Free:
http://www.atherosclerosis-journal.com/article/S0021-9150(13)00446-2/pdf

 

Jacobson TA. A new pure Ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Exp Rev Cardiovasc Drugs. 2012;10:687-695.
http://informahealthcare.com/doi/pdf/10.1586/erc.12.56

 

Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5-18.
http://www.lipidjournal.com/article/S1933-2874%2811%2900745-8/abstract

 
RECENT AMARIN-SUPPORTED SCIENTIFIC PRESENTATIONS

Mason RP, Jacob RF, Dawoud H, Alhumaid H, Mahmud FJ, Sherratt SCR, Malinski T. Eicosapentaenoic acid, but not other TG-lowering agents, reversed hyperglycemia-induced rat endothelial cell dysfunction and enhanced the benefits of atorvastatin active metabolite ex vivo [abstract 2178-PUB]. Diabetes. 2016;65(suppl 1):A554.

Mason RP, Jacob RF, Dawoud H, Wagner MR, Mahmud FJ, Sherratt SCR, Malinski T. Eicosapentaenoic acid and atorvastatin active metabolite, alone or in combination, reversed glucose- and oxidized LDL-induced endothelial dysfunction measured ex vivo in rats [abstract]. J Am Coll Cardiol. 2016;67(suppl):2320.

Sherratt S, Mason RP, Jacob R. Eicosapentaenoic acid reduces hyperglycemia-induced small dense low-density lipoprotein oxidation in vitro differently from docosahexaenoic acid [abstract 163]. J Clin Lipidol. 2016;10:701.
http://www.lipidjournal.com/article/S1933-2874(16)30112-X/fulltext

AMERICAN ACADEMY OF FAMILY PHYSICIANS

Crandell JR. Reductions in low-density lipoprotein cholesterol and particle concentration and improvements in other parameters of dyslipidemia in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk following switch from EPA+DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl). Presented at: The American Academy of Family Physicians conference, September 29-October 3, 2015, Denver, Colorado.

AMERICAN COLLEGE OF CARDIOLOGY

Mason RP, Jacob RF, Dawoud H, Wagner MR, Mahmud FJ, Sherratt SCR, Malinski T. Eicosapentaenoic acid and atorvastatin active metabolite, alone or in combination, reversed glucose- and oxidized LDL-induced endothelial dysfunction measured ex vivo in rats [abstract]. J Am Coll Cardiol. 2016;67(suppl):2320.
http://content.onlinejacc.org/article.aspx?articleid=2508618#tab1

AMERICAN DIABETES ASSOCIATION

Mason RP, Jacob RF, Dawoud H, Alhumaid H, Mahmud FJ, Sherratt SCR, Malinski T. Eicosapentaenoic acid, but not other TG-lowering agents, reversed hyperglycemia-induced rat endothelial cell dysfunction and enhanced the benefits of atorvastatin active metabolite ex vivo [abstract 2178-PUB]. Diabetes. 2016;65(suppl 1):A554.

BIOPHYSICAL SOCIETY

Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid (EPA), but not other triglyceride-lowering agents, inhibits glucose-induced changes in membrane width and cholesterol domain formation through a potent antioxidant mechanism [abstract 2877-Pos]. Biophys J. 2016;110:582a-3a.
http://www.cell.com/biophysj/pdf/S0006-3495(15)04296-4.pdf

Sherratt SCR, Shrivastava S, Jacob RF, Chattopadhyay A, Mason RP. Docosahexaenoic acid (DHA), but not eicosapentaenoic acid (EPA), increases both membrane fluidity and cholesterol crystalline domain formation in lipid vesicles [abstract 2879-Pos]. Biophys J. 2016;110:583a.
http://www.cell.com/biophysj/pdf/S0006-3495(15)04298-8.pdf

DEUEL CONFERENCE ON LIPIDS

Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid (EPA) inhibited cholesterol domain formation and lipid oxidation while preserving bilayer width in model membranes exposed to oxidative stress or high cholesterol levels [abstract]. Presented at: The DEUEL Conference on Lipids, March 1-4, 2016, Napa Valley, California.

NATIONAL LIPID ASSOCIATION

Sherratt S, Mason RP, Jacob R. Eicosapentaenoic acid reduces hyperglycemia-induced small dense low-density lipoprotein oxidation in vitro differently from docosahexaenoic acid [abstract 163]. J Clin Lipidol. 2016;10:701.
Free:
http://www.lipidjournal.com/article/S1933-2874(16)30112-X/fulltext

Reddy K, Chowdhury S. Improvements in carotid artery intima-media thickness with icosapent ethyl in three patients with non-HDL-C >130 mg/dL: a case series [abstract 167]. J Clin Lipidol. 2016;10:702-703.
http://www.lipidjournal.com/article/S1933-2874(16)30116-7/fulltext

WORLD CONGRESS ON INSULIN RESISTANCE, DIABETES & CARDIOVASCULAR DISEASE

Castaldo Reddy KJ, Chowdhury S. Improvements in HOMA-IR and atherogenic dyslipidemia by a combination of 10% loss of body weight and prescription eicosapentaenoic acid (icosapent ethyl) in a patient with diabetes mellitus and statin intolerance [abstract]. Endocr Pract. 2016;22:36A-7A.

Castaldo RS. Lipid effects of switching from fibrate therapy to the prescription omega-3 therapy, icosapent ethyl, in statin-treated patients: a retrospective case series [abstract]. Endocr Pract. 2016;22:23A.

THE CARDIOVASCULAR DISEASE PREVENTION CONFERENCE

Crandell J, Tartaglia C, Tartaglia J. Retrospective case series of lipid effects in patients switched from EPA + DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl) [abstract 124]. Clin Cardiol. 2015;38(suppl 1):12.

AMERICAN DIABETES ASSOCIATION

Mason RP, Jacob RF. Eicosapentaenoic acid (EPA) reduces glucose-induced small dense low-density lipoprotein oxidation in vitro in a manner distinct from other triglyceride-lowering agents and vitamin E [abstract 705-P]. Diabetes. 2015;64(suppl 1):A178-A179. Posting of the abstract is pending permission by the Journal Diabetes.

AMERICAN COLLEGE OF CARDIOLOGY

Mason RP, Jacob R, Corbalan JJ, Malinski T. Eicosapentaenoic acid reduces small dense low density lipoprotein oxidation and improves endothelial function in vitro as compared to other triglyceride-lowering agents [abstract]. J Am Coll Cardiol. 2015;65:A2139.

DEUEL CONFERENCE ON LIPIDS

Mason RP, Jacob RF, Corbalan J, Malinski T. Combination treatment with eicosapentaenoic acid and atorvastatin active metabolite reverses endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract]. Presented at the Deuel Conference on Lipids, March 3-6, 2015, Monterey, California.

NATIONAL LIPID ASSOCIATION

Mason RP, Jacob RF. Eicosapentaenoic acid (EPA), but not other TG-lowering agents, reduces cholesterol domain levels in atherosclerotic-like model membranes [abstract 176]. J Clin Lipidol. 2015;9:466.

Mason RP, Jacob RF, Corbalan JJ, Malinski T. Combination eicosapentaenoic acid and statin treatment reversed endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract]. J Clin Lipidol. 2014;8:342-343.

Mason RP, Jacob RF. Eicosapentaenoic acid inhibited glucose-induced membrane lipid peroxidation and cholesterol crystalline domain formation [abstract]. J Clin Lipidol. 2014;8:343.

Mason RP, Jacob RF, Gerard SA. Eicosapentaenoic acid (EPA) inhibits the formation of membrane cholesterol crystalline domains by a potent antioxidant mechanism [abstract]. J Clin Lipidol. 2013;7:272.

Mason RP, Jacob R, Beauregard G, Rowe J. Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors [abstract]. J Clin Lipidol. 2011;5:201.

Jacobson T, Soni P, Glickstein S, Rowe J. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol: a critical review [abstract]. J Clin Lipidol. 2011;5:200-201.



This page was last updated on February 10, 2017.